Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept versus tacrolimus in primary membranous nephropathy (AIS-D10)
jRCT2051250206Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of povetacicept in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Complete clinical remission (CR1) at Week 104. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
povetacicept
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on jRCT2051250206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250206.